Health and economic impact associated with a quadrivalent HPV vaccine in Italy. (Articolo in rivista)

Type
Label
  • Health and economic impact associated with a quadrivalent HPV vaccine in Italy. (Articolo in rivista) (literal)
Anno
  • 2009-01-01T00:00:00+01:00 (literal)
Alternative label
  • Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N. (2009)
    Health and economic impact associated with a quadrivalent HPV vaccine in Italy.
    in Gynecologic oncology (Print); Elsevier BV, Amsterdam (Paesi Bassi)
    (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori
  • Mennini FS; Giorgi Rossi P; Palazzo F; Largeron N. (literal)
Pagina inizio
  • 370 (literal)
Pagina fine
  • 376 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume
  • 112 (literal)
Rivista
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#pagineTotali
  • 7 (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroFascicolo
  • 2 (literal)
Note
  • ISI Web of Science (WOS) (literal)
  • Scopu (literal)
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni
  • Centre for Health Economics and Management (CHEM - CEIS Sanità), Faculty of Economics and Faculty of Science, University of Rome \"Tor Vergata\", Italy Laziosanità (Agency for Public Health), Lazio Region, Rome, Italy National Research Council, Institute of Research on Population and Social Policies (CNR-IRPPS), Rome, Italy Sanofi pasteur MSD, Lyon, France (literal)
Titolo
  • Health and economic impact associated with a quadrivalent HPV vaccine in Italy. (literal)
Abstract
  • Abstract Objective The aim of this study was to determine the health impact and cost-effectiveness of introducing a human papillomavirus (HPV) vaccination programme with a quadrivalent vaccine alongside the existing cervical cancer screening programme in comparison to the current context in Italy. Methods A US Markov model was adapted to the Italian context, assuming under base case 80% vaccine coverage rate, lifetime duration of protection in a cohort of girls aged 12 years and discount rates of 1.5% and 3% for health benefits and costs, respectively, and estimating direct medical costs. Results The HPV vaccination in association with the current screening programme would allow to avoid 1432 cases of cervical cancer (- 63.3%) and 513 deaths (- 63.4%) compared to screening only, with an incremental cost-effectiveness ratio (ICER) of EUR9569 per additional quality-adjusted life-year (QALY) gained. The sensitivity analysis highlighted that this model was robust to all parameters presenting uncertainties as the ICERs ranged from EUR2,781 to EUR48,122 per QALY gained. Conclusion This study showed that HPV vaccination in adolescent girls would be a beneficial and cost-effective public health programme in Italy. (literal)
Editore
Prodotto di
Autore CNR
Insieme di parole chiave

Incoming links:


Prodotto
Autore CNR di
Editore di
Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#rivistaDi
Insieme di parole chiave di
data.CNR.it